BACKGROUND: The prevalence of HIV/hepatitis B virus (HBV) co-infection in South Africa ranges from 4.8% to 17% using the standard marker surface antigen (hepatitis B surface antigen, HBsAg) for chronic active HBV infection. However, sensitive molecular techniques for detecting HBV DNA in serum can detect occult HBV infection. We report the first observational prospective study of occult HBV infection in HIV-positive people in South Africa. METHODS: Five hundred and two patients attending an urban hospital were screened for HBV using serological testing for HBsAg, core antibody (anti-HBc), and surface antibody (anti-HBs). DNA was analyzed using real-time quantitative PCR to determine the HBV viral load. RESULTS: Of the 502 participants, 24 (4.8%) were HBsAg-positive and 53 (10.6%) were positive for anti-HBc alone. Of these 53, screening for occult disease was carried out in 43, of whom 38 (88.4%) were positive. The mean HBV viral load was 2.8 x 10(4) copies/ml (range 1 x 10(2) to 1 x 10(6) copies/ml). CONCLUSIONS: Combining the participants with positive HBsAg and occult HBV DNA results, the prevalence of HBV increases from 4.8% (HBsAg alone) to 12.4%. While the clinical impact of occult HBV infection is unclear, consideration should be given to changing the guidelines to recommend dual HBV therapy for the treatment of co-infected patients in the developing world.
BACKGROUND: The prevalence of HIV/hepatitis B virus (HBV) co-infection in South Africa ranges from 4.8% to 17% using the standard marker surface antigen (hepatitis B surface antigen, HBsAg) for chronic active HBV infection. However, sensitive molecular techniques for detecting HBV DNA in serum can detect occult HBV infection. We report the first observational prospective study of occult HBV infection in HIV-positive people in South Africa. METHODS: Five hundred and two patients attending an urban hospital were screened for HBV using serological testing for HBsAg, core antibody (anti-HBc), and surface antibody (anti-HBs). DNA was analyzed using real-time quantitative PCR to determine the HBV viral load. RESULTS: Of the 502 participants, 24 (4.8%) were HBsAg-positive and 53 (10.6%) were positive for anti-HBc alone. Of these 53, screening for occult disease was carried out in 43, of whom 38 (88.4%) were positive. The mean HBV viral load was 2.8 x 10(4) copies/ml (range 1 x 10(2) to 1 x 10(6) copies/ml). CONCLUSIONS: Combining the participants with positive HBsAg and occult HBV DNA results, the prevalence of HBV increases from 4.8% (HBsAg alone) to 12.4%. While the clinical impact of occult HBV infection is unclear, consideration should be given to changing the guidelines to recommend dual HBV therapy for the treatment of co-infected patients in the developing world.
Authors: Vincent Lo Re; Ian Frank; Robert Gross; Janel Dockter; Jeffrey M Linnen; Cristina Giachetti; Pablo Tebas; John Stern; Marie Synnestvedt; A Russell Localio; Jay R Kostman; Brian L Strom Journal: J Acquir Immune Defic Syndr Date: 2007-03-01 Impact factor: 3.731
Authors: Christopher J Hoffmann; Salome Charalambous; Chloe L Thio; Desmond J Martin; Lindiwe Pemba; Katherine L Fielding; Gavin J Churchyard; Richard E Chaisson; Alison D Grant Journal: AIDS Date: 2007-06-19 Impact factor: 4.177
Authors: Charles S Chasela; Athena P Kourtis; Patrick Wall; Jan Drobeniuc; Caroline C King; Hong Thai; Eyasu H Teshale; Mina Hosseinipour; Sascha Ellington; Mary B Codd; Denise J Jamieson; Rod Knight; Patricia Fitzpatrick; Saleem Kamili; Irving Hoffman; Dumbani Kayira; Noel Mumba; Deborah D Kamwendo; Francis Martinson; William Powderly; Chong-Gee Teo; Charles van der Horst Journal: J Hepatol Date: 2013-11-06 Impact factor: 25.083
Authors: Eleanor A Powell; Maemu P Gededzha; Michael Rentz; Nare J Rakgole; Selokela G Selabe; Tebogo A Seleise; M Jeffrey Mphahlele; Jason T Blackard Journal: J Med Virol Date: 2014-08-27 Impact factor: 2.327
Authors: Eleanor A Powell; Ceejay L Boyce; Maemu P Gededzha; Selokela G Selabe; M Jeffrey Mphahlele; Jason T Blackard Journal: J Gen Virol Date: 2016-03-31 Impact factor: 3.891